| Dr James Sanford Mayer, DO, | |
|
7860 Kula Hwy, Kula, HI 96790-7404 | |
| (808) 876-1984 | |
| (808) 876-1984 |
| Full Name | Dr James Sanford Mayer |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 7860 Kula Hwy, Kula, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851559744 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DOS 00341 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Sanford Mayer, DO, Po Box 1237, Kula, HI 96790-1237 Ph: (808) 876-1984 | Dr James Sanford Mayer, DO, 7860 Kula Hwy, Kula, HI 96790-7404 Ph: (808) 876-1984 |
News Archive
Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.
Scientists have manufactured a synthetic form of peptide to combat viral infections, with tests already conducted on HSV-1 as well as SARS-CoV-2.
"Results from a groundbreaking trial of three drugs given in combination - one of them completely new and one not yet licensed for this use - killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.
The uncoupling Protein 1 (UCP1) is found exclusively in brown adipose tissue. Until some years ago it was thought that only babies and hibernating animals had brown adipose tissue, but since then it also has been found in adults, so UCP1 could be useful in the fight against obesity.
Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.
› Verified 1 days ago
Dr. Nicole L Wade, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Keokea Pl, Kula, HI 96790 Phone: 808-876-4331 Fax: 808-876-4332 | |
Maria S Kriekenbeek, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 100 Keokea Pl, Kula, HI 96790 Phone: 808-876-4415 Fax: 808-876-4385 | |
Alice C Svoboda, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Keokea Pl, Kula, HI 96790 Phone: 808-876-4331 Fax: 808-876-4332 | |
Nicole M. Apoliona, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Keokea Pl, Kula, HI 96790 Phone: 808-876-4331 Fax: 808-878-4332 |